VOLUME 10 NUMBER 1 • MARCH 2013
31
SA JOURNAL OF DIABETES & VASCULAR DISEASE
REVIEW
used. It is imperative to treat all risk factors associated with the
neuropathy and glycaemic control should be gradually optimised.
Care should be taken to evaluate and treat depression and sleep
disorders.
In the future it is hoped that PDPN will be added to the list
of PMB conditions and reimbursed in full and without prejudice
by medical aids and medical insurance funders. PDPN should be
recognised as a potentially serious, debilitating chronic condition,
a common cause of morbidity in diabetic patients and a difficult
therapeutic challenge for doctors.
References
1.
Bouhassira D, Attal N. Diagnosis and assessment of neuropathic pain: The saga
of clinical tools.
Pain
2011;
152
: S74–S83.
2.
Writing team for the DCCT/EDIC research group: Effect of intensive therapy on
the microvascular complications of type 1 diabetes mellitus.
J Am Med Assoc
2002;
287
: 2563–2569.
3.
Dyck PJ, Kratz KM, Karnes, JL,
et al
. The prevalence by staged severity of various
types of diabetic neuropathy, retinopathy, and nephropathy in a population –
based cohort: the Rochester Fiabetic Neuropathy Study.
Neurology
1993;
43
:
817–824.
4.
Horowitz SH. The diagnostic workup of patients with neuropathic pain.
Anesthesiology Clin
2007;
25
: 699–708.
5.
Evidence-based guideline: Treatment of painful diabetic neuropathy, April 2011.
Report of the American Academy of Neurology, the American Association of
Neuromuscular and Electro diagnostic Medicine, and the American Academy of
Physical Medicine and Rehabilitation.
6.
Dabby R, Sadeh M, Lampi Y,
et al
. Acute painful neuropathy induced by rapid
correction of serum glucose levels in diabetic patients.
Biomed Pharmacol
2009;
63(10): 707–709.
7.
Gibbons CH, Freeman R. Treatment -induced diabetic neuropathy – a reversible
painful autonomic neuropathy.
Ann Neurol
2010;
67
: 534–541.
8.
Turk DC.
Are pain syndromes acute or chronic diseases?
Clin J Pain
2000;
16
:
279–280.
9.
Belgrade MJ.
Following the clues to neuropathic pain.
Postgrad Med
1999;
106
:
127–140.
10. Attal N, Cruccu G, Baron R,
et al.
EFNS guidelines on the pharmacological
treatment of neuropathic pain: 2009 revision.
Eur J Neurol
2010;
17
(9): 1113–
e88.
11. Huizinga MM, Peltier A. Painful diabetic neuropathy: A management-centered
review.
Clin Diabetes
2007;
25
(1): 6–15.
12. Lin H, Quan D. Diabetic neuropathic pain management. emedicine.medscape.
13. Hovaguimian A, Gibbons CH. Clinical approach to the treatment of painful
diabetic neuropathy.
Ther Adv Endocrinol Metab
2011;
2910
: 27–38.
14. Bril V, England J, Franklin GM,
et al.
Evidence-based guideline: Treatment of
painful diabetic neuropathy.
Neurology
2011;
76
: 1758.
15. Haanpaa M, Attal N, Backonja M,
et al.
NeuPSIG guidelines on neuropathic pain
assessment.
Pain
2011;
152
: 14–27.
16. Dworkin R, O’Connor AB, Audette J,
et al.
Recommendations for the pharma-
cological management of neuropathic pain: an overview and literature update.
Mayo Clin Proc
2010;
85
(3) Suppl: S3–S14.
17. Neuropathic pain: The pharmacological management of neuropathic pain in
adults in non-specialist settings. Clinical Guidelines CG96 March 2010.
18. Jensen TS, Backonja M, Hernandez J. New perspectives on the management of
diabetic peripheral neuropathic pain.
Diabetes Vasc Dis Res
2006;
3
(2): 108–119.
19. Kroenke K, Krebs EE. Pharmacotherapy of chronic pain: a synthesis of
recommendations from systematic reviews.
Gen Hosp Psychiatry
2009;
31
(3):
206–219.
20. Goldstein DJ, Lu Y, Detke MJ,
et al
. Duloxetine vs placebo in patients with painful
diabetic neuropathy.
Pain
2005;
116
: 109–118.
21. Wenicke JF, Pritchett YL, D’Souza DN,
et al
. Duloxetine decreases the pain of
diabetic neuropathy.
Neurology
2006;
67
: 1411–1420.
22. Raskin J, Prithett YL, Wang F,
et al.
A double-blind multicentre trial comparing
duloxetine with placebo in the management of diabetic peripheral neuropathic
peripheral pain.
Pain Med
2005;
6
: 346–356.
23. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological
mechanisms, and treatment.
Lancet Neurol
2010;
9
: 807–819.
24. Gibbons CH, Illigens BM, Wang N, Freeman R. Quantification of sudomotor
innervation: A comparison of three methods. Muscle Nerve 2010;
42
: 112--119.
25. Polydefkis M, Hauer P, Sheth S,
et al
. The time course of epidermal nerve fibre
regeneration:studies in normal controls and in people with diabetes with and
without neuropathy.
Brain
2004;
127
: 1606--1615.
26. Donofrio P, Walker F, Hunt V,
et al
.; Capsaicin study group. Treatment of painful
diabetic neuropathy with topical capsaicin.
Arch Intern Med
1991;
151
: 2225--
2229.
27. Donofrio P, Walker F, Hunt V,
et al
.; Capsaicin study group. Effect of treatment
with capsaicin on daily activities of patients with painful diabetic neuropathy.
Diabetes Care
1992;
15
(2): 159--165.
28. Gieckmann A, Kriebel M, Andriambeloson E, Ziegler D, Elminger M. Treatment
with actovegin improves sensory nerve function and pathology in streptozocin-
diabetic rats via mechanisms involving inhibition of PARP activation.
Exp Clin
Endocrin Diabetes
2012;
120
(3): 132–138.
29. Ziegler D, Movsesvan L, Mankovsky B,
et al.
Treatment of symptomatic
polyneuropathy with actovegin in type 2 diabetic patients.
Diabetes Care
2009;
32
(8): 1479–1484.
30. Dray A. Neuropathic pain: emerging treatments.
Br J Anaesthesia
2008;
101
(1):
48–58.
31. Boulton AJM, Arezzo, Vinik AI,
et al.
Diabetic neuropathies: a statement by the
American Diabetes Association.
Diabetes Care
2006;
28
: 956–962.
Recommended reading
• Backonja M, Beydoun A,
Edwards KR,
et al.
Gabapentin for the symptomatic
treatment of painful neuropathy in patients with diabetes mellitus
. J Am Med
Assoc
1998;
280
: 1831–1836.
•
Eastman RC. Neuropathy in diabetes. In:
Diabetes in America,
2nd edn. Bethesda,
MD: National Diabetes Data Group, National Institutes of Health; NIH publication
No 95-1468; 1995: 339–347.
•
Boulton AJM Vinik AI, Arezzo JC,
et al.
Diabetic somatic neuropathies.
Diabetes
Care
2004;
27
: 1458–1486.
•
Ziegler Gries FA, Spuler M, Lessmann F. Diabetic Cardiovascular Autonomic
Neuropathy Multicenter Study Group. The epidemiology of diabetic neuropathy
.
J Diabetes Complications
1992;
6
: 49–57.
• Young MJ, Boulton AJM, Macleod AF,
et al.
A multicenter study of the prevalence
of diabetic peripheral neuropathy in the United Kingdom hospital clinic
population.
Diabetologia
1993;
36
: 150–154.
•
Polydefkis M,
Griffin JW, McArthur J
. New insights into diabetic polyneuropathy.
J Am Med Assoc
2003;
290
: 1371–1376.
•
Eli Lilly in-house file data (duloxetine).
• Ko S-H, Kwon HS, Yu JM,
et al.
Comparison of the efficacy and safety of tramadol/
acetaminophen combination therapy and gabapentin in the treatment of painful
diabetic neuropathy.
Diabetic Med
2010;
27
(9): 1033–1040.
•
Vinik A, Ullal J, Parson HK, Casellini CM.
Nature Clin Pract Endocrinol Metab
2006;
2
: 269–281.
•
Freeman R, Tesfaye D, Freynhagen R, Boulton A. Pain: the final frontier –
Emerging opinions in painful neuropathy. Pfizer-sponsored symposium. Abstracts
and summaries of lectures (references quoted in the proceedings brochure).
•
Erin L St Onge and Shannon a Miller. Pain associated with Diabetic Peripheral
Neuropathy. Jefferson University Continuing Education Credit. Feb 2008
•
Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for
preventing and treating diabetic neuropathy.
Cochrane Database Syst Rev
16 Mar
2011; CD007938.
•
Haanpää ML, Gourlay GK, Kent JL,
et al.
Treatment considerations for patients
with neuropathic pain and other medical comorbidities.
Mayo Clin Proc
2010;
85
(3) Suppl: S15–S25.
•
Fink E, Oaklander AL. Small fiber neuropathy: answering the burning questions.
Sci Aging Knowl Environ
2006;
2006
(6): 7.
•
Bouhassira D, Attal N. Diagnosis and assessment of neuropathic pain: The saga of
clinical tools.
Pain
2011;
152
: S74–S83.
•
A new definition of neuropathic pain.
Pain
2011;
152
: 2204–2205
•
Harriot A, Gold MS. Contribution of primary afferent channels to neuropathic
pain.
Curr Pain Headache Rep
2009;
13
(3): 197–207.
•
Stillman M. Clinical approach to patients with neuropathic pain.
Cleveland Clin J
Med
2006; 73(8): 726–736.
•
Ziegler D, Rathman W, Dickhaus T. Neuropathic pain in diabetes, prediabetes and
normal glucose tolerance: the MOICA/KORA Augsburg Surveys S2 and S3.
Pain
Med
2009;
10
(2): 393–400.
